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CancerThe a1,2-fucosyltransferase activity in pancreatic tumors is much lower compared to normal pan-
creatic tissue. Here we show that hypoxia inducible factor (HIF) 1a is constitutively expressed in
the pancreatic cancer cell lines Pa-Tu-8988S and Pa-Tu-8988T and suppresses the expression of
the a1,2-fucosyltransferase genes FUT1 and FUT2. Down regulation of HIF-1a expression resulted
in elevated FUT1 and FUT2 transcript levels and an increased expression of a1,2-fucosylated glycan
structures on the surface of these cells. In conclusion, our data are the ﬁrst to identify HIF-1a as a
suppressor of FUT1/2 expression, thereby regulating a1,2-fucosylation of cell-surface glycans.
 2015 Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies.1. Introduction 4GlcNAc-R glycans to form H type 1 and 2 antigens, respectively.Cell surface glycans undergo dramatic structural changes dur-
ing progression of cancer. The resulting glycans thereby alter
important properties of the cancer cells, and can for example facil-
itate their migration or affect their recognition by immune cells [1–
3]. One of the factors that contributes to the generation of aberrant
glycan structures is a disturbed regulation of expression of speciﬁc
glycosyltransferases, enzymes that catalyze the biosynthesis of
glycan structures [4].
Several studies have indicated a relationship between the risk of
pancreatic cancer (PC) and ABO blood group (BG) status [5–7]. The
a1,2-fucosyltransferases FUT1 and FUT2 catalyze the addition of
fucose to the galactose residues in Galb1–3GlcNAc-R and Galb1–These H-type antigens are the precursor structures of the BG A
and B antigens, and in addition contribute to the synthesis of
a1,2-fucosylated Lewis structures such as Lewis Y (LeY, Fuca1–2
Galb1–4(Fuca1–3)GlcNAc-R). Remarkably, a decreased expression
of both the H and the LeY antigen has been observed in PC [4,8],
which may be due to a deregulated expression of FUT1 and/or
FUT2. However, little is known about the regulation of these genes.
Hypoxia-inducible transcription factors (HIFs) are known to
regulate a multitude of genes in cancer, including some glycosyl-
transferases [9], and we hypothesized that they might play a role
in regulation of FUT1 and/or FUT2 expression in PC. After synthesis,
HIF-a proteins are either degraded or stabilized against proteaso-
mal destruction under hypoxic conditions and translocated into
the nucleus. There they can act as functional transcription factors
after heterodimerization with constitutively expressed HIF-b sub-
units [10]. The functional HIF heterodimer binds to the hypoxia
responsive elements (HREs) present in gene promoters, thereby
regulating downstream target genes [11]. Three HIF isoforms have
been described (HIF-1, -2 and -3). HIF-1a is ubiquitously expressed
in almost all tissues, whereas HIF-2a is tissue speciﬁc, and is
expressed under hypoxia in some tissues including pancreas [12].
Their protein structures are rather similar, and they display com-
mon, but also unique downstream gene induction patterns
[10,13–15]. Remarkably, in PC the presence of constitutively
expressed, hypoxia-independent, HIF-1 has been reported [16].
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expressed in two pancreatic ductal adenocarcinoma (PDAC) cell
lines, Pa-Tu-8988S (PaTu-S) and Pa-Tu-8988T (PaTu-T), which
show opposite growth characteristics and metastatic potential
[17,18]. These cell lines provide an attractive model system to
study regulatory aspects of a1,2-fucosylation, as they originate
from the same patient, thereby excluding a different congenital
background. Our data demonstrate that the PDAC cell line PaTu-T
displays a constitutive and higher HIF-1a expression compared
to PaTu-S, and acts as a suppressor of FUT1 and FUT2 expression.
These data show that HIF-1a can regulate a1,2-fucosylation of
cell-surface glycans, and enhance our understanding of the regula-
tion of glycosylation in cancer.
2. Materials and methods
2.1. Materials, cells
DMEM medium, fetal bovine serum (FBS), penicillin and strep-
tomycin were from Gibco, KC7F2 from Tocris Biosciences (R&D
Systems), small interfering RNAs (iRNAs) and the
SilencerNegative control from Ambion (Life Technology), and
Lipofectamine RNAiMax and Opti-MEM from Invitrogen (Life
Technology). Biotinylated lectin Ulex europaeus (UEA-1) was from
E-Y Laboratories (USA). Antibodies (Abs) used were: mouse
anti-HIF-1a NB100-105 and rabbit anti-HIF-2a (Novus
Biologicals, UK), rabbit anti-HIF-1a (Cayman Chemical, USA),
mouse IgM anti-Blood group A and anti-Blood group B (Sanquin,
Netherlands) and mouse anti-Lewis Y (Fuca1–2Galb1–4(Fuca1–3
)GlcNAc-R, LeY) (Calbiochem, Germany). Secondary reagents used,
were goat anti-rabbit Alexa Fluor 488 (AF488), goat anti-mouse
AF488 and AF647, streptavidin AF488 and AF647 (Molecular
Probes, Invitrogen, USA) and Horseradish peroxidase-conjugated
(HRP) anti-rabbit/goat Abs (Dako, Belgium). Rhodamine phalloidin
and HOECHST were from Molecular Probes and Life Technologies
(Invitrogen, USA), respectively. Roti-Block blocking buffer was
acquired from Roth (Karlsruhe, Germany).
Pa-Tu-8988S (PaTu-S) and Pa-Tu-8988T (PaTu-T) cell lines were
purchased from DSMZ culture bank (Braunschweig, Germany) and
cultured as described [17]; SW480 and HTC116 colon cancer cell
lines were kindly provided by Dr. Remond Fijneman (Dep.
Pathology, VUmc, Amsterdam), and cultured as described for PC
cells.
2.2. Quantitative real-time PCR (qRT-PCR)
mRNA was isolated from cells using the mRNA Capture kit
(Roche, Basel, Switzerland) according to manufacturer’s guidelines.
Reverse Transcription System kit (Promega) was used for cDNA
synthesis. Oligonucleotides (Table 1) were designed (http://www.
ncbi.nlm.nih.gov/tools/primer-blast/index.cgi) and synthesized by
Invitrogen (USA). PCR reactions and relativemRNA abundance anal-
ysis were performed as described [17], using glyceraldehyde-3-
phosphate dehydrogenase gene (GAPDH) as a reference.
2.3. Flow cytometry
Cells were incubated with anti-LeY (5 lg/mL), anti-BG A and B
(undiluted) and UEA1-biotin (15 lg/mL) for 1 h at 37 C in TSM
(20 mM Tris–HCl, pH 7.4, 150 mM NaCl, 1 mM CaCl2 and 2 mM
MgCl2) containing 1% bovine serum albumin (BSA), followed by a
30 min incubation with ﬂuorescent Streptadivin or secondary
Abs. The mean ﬂuorescence intensity (MFI) of cell populations
was determined using a FACSCalibur ﬂow cytometer (Becton
Dickinson), with Summit software (Dako Colorado, Inc, CO, USA).2.4. Western-blotting
150 lg proteins of whole cell lysates were separated by SDS–
PAGE and transferred to nitrocellulose membranes (Whatman
Protran, Sigma). Blots were incubated with rabbit anti-HIF-1a
(4 lg/mL) and goat anti-Actin Abs (0.1 lg/mL, Santa Cruz
Biotechnology, USA) as endogenous control overnight at 4 C, and
subsequently stained with anti-rabbit HRP or anti-goat HRP anti-
bodies (0.125 lg/mL) at room temperature (RT). Immunoreactive
proteins were visualized by ECL (Advanstra, USA).
2.5. Immunocytochemistry (ICC)
Cells were ﬁxed 24 h after seeding, with 100% methanol for
15 min, and stained with mouse anti-HIF-1a (20 lg/mL) overnight
at 4 C, followed by anti-mouse AF488 for 1 h at RT. Background
was deﬁned by incubation with anti-mouse AF488 Abs only.
Nuclei were stained with HOECHST (1 lg/mL in PBS) and actin by
rhodamine phalloidin (1:5000 in PBS). After embedding (Mowiol,
Kuraray Poval, Germany), images of at least 600 cells were analyzed
(Leica M6000 B microscope, DFC350FXR2-095903305 Camera,
LASAF software (Leica Microsystems, Germany)).
2.6. Inhibition of HIF-1a
Optimal concentrations of KC7F2 (in dimethyl sulfoxide, DMSO)
were added 24 h after seeding (0.5  106 cells) to PaTu-T and
PaTu-S (50 lM), SW480 and HTC116 (25 lM) for 16 h (for
qRT-PCR) or 2–3 days (for ﬂow cytometry). Mock treated cells were
treated similarly with DMSO without KC7F2.
For HIF-1a and HIF-2a Knock Down (KD) pre-designed and neg-
ative control iRNAs (Mock) were used (4–5 nM, optimal transfec-
tion efﬁciency). Transfections were performed according to
Invitrogen guidelines for reverse transfection in a 24-wells plate,
using 1 lL Lipofectamine RNAiMax and 100 lL Opti-MEM med-
ium. HIF-1a and HIF-2a mRNA levels were measured for KD efﬁ-
ciency 24 h after transfection using qRT-PCR. GAPDH expression
was not affected by HIF KD in these cells, as determined by com-
parison of GAPDH levels with b2-microglobuline levels (data not
shown).
2.7. Statistical analysis
Data are presented as mean ± S.E.M. of at least 3 independent
experiments. Statistics were performed using paired t-tests.
Signiﬁcant values are indicated with * for P 6 0.05 and ** for
P 6 0.01.
3. Results
3.1. Differential expression of FUT1 and FUT2 in PaTu-S and PaTu-T
cells
To increase our understanding of the regulation of
a1,2-fucosylation, we determined the mRNA levels of FUT1 and
FUT2 in the PDAC cell lines PaTu-S and PaTu-T. While originating
from a liver metastasis of one PDAC patient, these cell lines possess
opposite morphological and migratory capacities [17]. Our data
show that PaTu-S contains higher levels of FUT1 and FUT2 tran-
scripts compared to PaTu-T (Fig. 1A).
Next, the presence of glycans carrying terminal a1–2-linked
fucose (Fuc), catalyzed by FUT1 and/or FUT2 gene products, was
determined on these cells using antibodies (Abs) against the blood
group (BG) antigens A and B and LeY. Binding of anti-BG Abs, as
well as anti-LeY Abs to PaTu-S was demonstrated by ﬂow
Table 1
Oligonucleotides used in this study.
Gene Forward (50–30) Reverse (50–30)
HIF-1aa CGGCGCGAACGACAAGAAAAAGATA TCGCCGAGATCTGGCTGCAT
HIF-1ba AGGAGCGGTTTGCCAGGTCG TTGTTCCGTCGCCGCCGTTC
HIF-2aa CTTCCTGCGAACACACAAGC AGCTCCACCTGTGTAAGTCC
HIF-2ba TTGGAACGAGCCACACCTAC GTCCACTTTCAGCGAACCCT
FUT1b GCAGGCCATGGACTGGTT CCTGGGAGGTGTCGATGTTT
FUT2b CTCGCTACAGCTCCCTCATCTT CGTGGGAGGTGTCAATGTTCT
GAPDHc CCATGTTCGTCATGGGTGTG GGTGCTAAGCAGTTGGTGGTG
Beta 2-microglobulined TTTCATCCATCCGACATTG CGGCAGGCATACTCATCTTT
a Designed using software from http://www.ncbi.nlm.nih.gov/nuccore.
b Published in [38].
c Published in [17].
d Published in [39].
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Fig. 1. Higher a1,2-fucosylation in PaTu-S cells compared to PaTu-T cells. (A) Transcript levels of FUT1 and FUT2 genes in PaTu-S and PaTu-T cells. mRNA levels are shown as
relative abundance to the household reference gene GAPDH ± S.E.M. (B) Binding of antibodies against the blood groups (BG) A and B, and Lewis Y (Ley), to PaTu-S and PaTu-T
cells was determined by ﬂow cytometry. Schematic glycan structures of the glycan antigens are indicated. Results are shown as average mean ﬂuorescence intensity
(MFI) ± S.E.M. of P2 independent experiments in duplicate.
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cells was observed (Fig. 1B). In summary, these data indicate
higher FUT1 and FUT2 mRNA levels and a1,2-fucosyltransferase
activity in PaTu-S cells, compared to PaTu-T cells and establish
the value of the PaTu-S and PaTu-T cell lines as a model system
to study regulatory aspects of a1,2-fucosylation.
3.2. PaTu-T cells express higher HIF-1a levels compared to PaTu-S cells
In pancreatic tissue, both HIF-1a and HIF-2a are expressed in
ischemic conditions [12], whereas in PC the presence of constitu-
tively expressed, hypoxia-independent, HIF-1 has been reported
[16]. To evaluate the expression of HIF factors in PaTu-S and
PaTu-T under normoxic conditions, mRNA levels of HIF-1a,
HIF-1b, HIF-2a and HIF-2b were determined (Fig. 2). Interestingly,
when compared to PaTu-S cells the expression levels of both
HIF-1a and HIF-1b genes are more than 2-fold higher in PaTu-T
(Fig. 2A). These results indicate the possibility that higher levels
of stable HIF-1a/HIF-1b heterodimer may be formed in PaTu-T
than in PaTu-S cells. By contrast, HIF-2a is 16-fold less expressed
in PaTu-T, whereas HIF-2b is 36-fold more expressed in PaTu-T
compared to PaTu-S. These differences in expression make the for-
mation of the HIF-2 heterodimer in the cells less likely. Next, we
assessed the protein levels of HIF-1a in PaTu-S and PaTu-T cells.Using Western blot (Fig. 2B) we show expression in both cell lines,
with higher band intensity in PaTu-T whole cell extract at 116kDa
and 230kDa, corresponding to HIF-1a and the stable heterodimer
HIF-1, respectively. By contrast, no detectable expression of
HIF-2a was observed in both cell lines (data not shown). In addi-
tion, the expression and localization of HIF-1a protein was deter-
mined by immunocytochemistry in both PaTu-S and PaTu-T cells
(Fig. 2C). In PaTu-S a predominant cytoplasmatic distribution of
HIF-1a is visible in most cells, and a few cells presented staining
in the nucleus. In Patu-T, HIF-1a staining varied from homoge-
neous to localized foci in the cytoplasm, and a small percentage
of the cells (5%) showed no staining at all. Interestingly however,
HIF-1a is also frequently found within the nucleus in more than
50% of the PaTu-T cells, both in foci and in a homogeneous distri-
bution, suggesting an active role of HIF-1a in gene transcription.
3.3. HIF-1a suppresses FUT1/2 gene expression and a1,2-fucosylation
in PDAC cell lines
To assess whether HIF-1a can regulate a1,2-fucosylation, we
treated PaTu-T and PaTu-S cells with the HIF-1a inhibitor KC7F2
[19] for 3 days. After this treatment, cells were analyzed by ﬂow
cytometry using UEA-1 lectin and anti-LeY Abs to detect the pres-
ence of FUT1/2 gene products, the H antigen and LeY antigen,
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Fig. 2. HIF subunit expression and localization in PaTu-T and PaTu-S cells. (A) Transcript levels of HIF-1 and HIF-2 subunits in PaTu-S and PaTu-T. mRNA levels are shown as
relative abundance to the household reference gene GAPDH ± S.E.M. (B) Western blot of HIF-1a protein levels in PaTu-S and PaTu-T. Total proteins (150 lg) from whole-cell
extracts were analyzed by Western blotting using anti-HIF-1a Abs, and anti-actin Abs to verify similar protein loading. (C) Representative photographs of HIF-1a protein
expression using immunocytochemistry with magniﬁcation at 63. HIF-1a was detected using Alexa Fluor 488 binding to anti-HIF-1a Abs (green), actin was stained using
Phalloidin (red) and nuclear staining using HOESCHT (blue). Background staining was determined by substituting anti-HIF-1a Abs with PBS.
2362 A.I. Belo et al. / FEBS Letters 589 (2015) 2359–2366respectively (Fig. 3). Binding of UEA-1 and anti-LeY Abs to both
PaTu-T (Fig. 3A) and PaTu-S (Fig. 3B) cells treated with KC7F2
was signiﬁcantly increased compared to mock treated cells.
These results clearly indicate that inhibition of HIF-1a with
KC7F2 results in increased cell surface a1,2-fucosylation.
In addition, in PaTu-T cells KD of HIF-1a, which reduced HIF-1a
mRNA levels by 75% (Fig. 4A), resulted in an increase (>5-fold) of
both FUT1 and FUT2 transcript levels compared to mock treated
cells (Fig. 4B). Depletion of HIF-2a resulted in a slight,
non-signiﬁcant, increase in both FUT1 and FUT2 transcript levels,
which may be due to the slight decrease in HIF-1a levels. Threedays after iRNA treatment, binding of the lectin UEA-1 was mea-
sured to detect H-type glycans on the surface of PaTu-T. A signiﬁ-
cant increase in UEA-1 binding to the HIF-1a depleted cells was
observed (Fig. 4C). This was speciﬁc for HIF-1a KD, since depletion
of HIF-2a hardly affected UEA-1 binding. Also the binding of
anti-Ley was increased in the cells treated with HIF-1a iRNA
(Fig. 4D). In summary, the levels of FUT1/2 transcripts as well as
the glycan products synthesized by FUT1/2, are inversely corre-
lated with HIF-1a expression in PaTu-T cells, establishing that
HIF-1a acts as a repressor of FUT1 and FUT2 expression in PaTu-T
cells.
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Fig. 3. Chemical inhibition of HIF-1a increases a1,2-fucosylation. Binding of UEA1 lectin and anti-Ley antibody to PaTu-T (A) and PaTu-S (B) cells, 3 days after treatment with
the HIF-1a inhibitor KC7F2 (50 lM), as measured by ﬂow cytometry. Results are shown as the average fold change in MFI ± S.E.M. relative to the values of the mock treated
cells in P2 independent experiments carried out in duplicate.
BA
C
Fo
ld
 C
ha
ng
e 
(M
FI
)
UEA1
0
0.5
1.0
1.5
2.0
2.5
* **
n.s
Mock HIF-1α HIF-2αKD
D LewisY
0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
Fo
ld
 C
ha
ng
e 
(M
FI
)
Mock HIF-1α HIF-2αKD
HIF-1α
m
R
N
A
 e
xp
re
ss
io
n
Mock HIF-1α HIF-2α
0
2
4
6
8
10
12 n.s
**
KD
*
X10-3
HIF-2α
Mock HIF-1α HIF-2αKD
0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
m
R
N
A
 e
xp
re
ss
io
n
X10-3
*
FUT2
0
0.02
0.04
0.06
0.08
0.10
0.12
m
R
N
A
 e
xp
re
ss
io
n
Mock HIF-1α HIF-2αKD
X10-3
FUT1
0
0.02
0.04
0.06
0.08
0.10
0.12
m
R
N
A
 e
xp
re
ss
io
n
*
Mock HIF-1α HIF-2αKD
X10-3
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A.I. Belo et al. / FEBS Letters 589 (2015) 2359–2366 23633.4. HIF-1a suppresses FUT1/2 gene expression and a1,2-fucosylation
in colon cancer cell lines
To establish whether HIF-1a can downregulate
a1,2-fucosylation in other cells than PaTu-S and PaTu-T, we
deﬁned the relationship between HIF-1a expression and
a1,2-fucosylation in the colorectal cancer cell lines SW480 andHTC116. The results show that both cell lines expressed HIF-1a
(Fig. 5A) and that 16 h after KC7F2 treatment, higher FUT1 and
FUT2 transcript levels were observed in both cell lines (Fig. 5B).
In addition, the binding of UEA-1 lectin to both SW480 and
HTC116 and anti-LeY Abs to HTC116 was increased after 2 days
of treatment compared to mock treated cells (Fig. 5C). These
results clearly indicate that inhibition of HIF-1awith KC7F2 results
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lines SW480 and HTC116. These data suggest that HIF-1amay reg-
ulate a1,2-fucosylation in multiple tumor types.
4. Discussion
Previous studies have shown that HIF-1 is constitutively
expressed and present in stabilized form in PC via
hypoxia-independent mechanisms, which contribute to metastasis
and progression of the cancer [16,20]. HIF-1a can be induced and
stabilized by hypoxia-independent signaling pathways, such as
mTOR, ERBB2, and MAP/ERK kinase (MEK), which are commonly
altered and/or upregulated in cancer or through genetic alterations
such as the loss of the von Hippel-Lindau protein [21] and in HIF-1a
gene polymorphisms [16]. The present study shows a direct sup-
pressive effect of constitutive HIF-1a expression on the synthesis
of a1,2-fucosylated cell-surface glycans in the PDAC cell lines
PaTu-T and PaTu-S, via a decrease of the transcript levels of FUT1/2.
Changes in the surface glycosylation of cancer cells have been
associated with an altered invasive capacity of the cells. PaTu-T
shows strong metastatic properties both in vitro and in vivo in a
zebraﬁsh model, while PaTu-S cells display a more tumor-like
growth and low migratory capacity [17]. The low level of
a1,2-fucosylation in PaTu-T cells might contribute to the meta-
static properties of the PDAC cells. Down regulation of
a1,2-fucosylation can lead to enhanced levels of sialylated struc-
tures, since FUT1/2 competes with a2,3-sialyltransferases
(ST3GalTs) for the same precursor structures. Increased sialylation,associated with expression of FUT3, could lead to enhanced levels
of sialyl-LeX and sialyl-LeA [22,23], two well-known cancer mark-
ers [24] that contribute to the metastatic properties of cancer cells
via their interaction with selectins [25]. Thus, high levels of
a1,2-fucosylation could lead to relatively low sialyl-LeX levels
associated with a low metastatic capacity, similar as has been
shown by overexpression of FUT1 in colon cancer cells [26].
Furthermore, the H-antigen is the precursor structure of the BG A
and B antigens. Low levels of a1,2-fucosylation result in low
H-antigen levels, and thus low levels of BG A and B antigens. The
loss of these BG antigens have been associated to increased cellular
motility and resistance to apoptosis [4], relevant properties for
metastatic cancer cells.
Collectively, these data indicate that low levels of FUT1/2 could
promote metastasis in cancer cells which have the capacity to syn-
thesize other glycan moieties relevant for metastasis, such as
sialyl-LeX and/or sialyl-LeA. However, little is known about factors
that regulate a1,2-fucosylation. Many factors can inﬂuence the reg-
ulation of glycosylation patterns in cancer, including changes in the
expression levels of glycosyltransferase genes such as lack of
expression, due to loss of heterozygosity or promoter methylation,
or increase of gene expression or neoexpression [4,24,27]. We have
shown previously that FUT1 can be upregulated by tumor necrosis
factor-a [28]. Recently, it has been shown that in colon cancer cells
the transcription factor Elk-1 [29] and c-Jun in ovarian cancer cells
[30] can be involved in the transcriptional regulation of FUT1.
Our data demonstrate that HIF-1a functions as a suppressor in
the regulation of FUT1/2 in the PDAC cell line PaTu-T. In addition,
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and cell surface fucosylation in PaTu-S cells, and in the colon can-
cer cell lines SW480 and HTC116, indicating that this effect is not
restricted to PDAC cells. Our data are not directly in accordance
with recent data which show that FUT1 transcription was elevated
under hypoxic conditions in prostate cancer cells [31]. Whereas
hypoxia is known to induce HIF-1a expression, the role of HIF-1a
in the regulation of FUT1 was not investigated in the latter study,
leaving the possibility open that other hypoxia-induced factors
could be involved in the observed upregulation of FUT1 in prostate
cancer [32].
The mechanism by which HIF-1a suppresses FUT1/2 expression
has not been clariﬁed in this work, and future studies are required
to fully understand the function of this transcription factor in the
suppression of a1,2-fucosylation, and its relevance for cell migra-
tion and metastasis. Interestingly, results of studies on the tran-
scriptional regulation of the pig FUT1 gene demonstrated that
this gene possesses positive and negative regulatory elements in
the upstream non-coding region [31]. The negative regulatory area
impaired transcription initiation even though abundant cis-acting
elements and transcription factor-binding loci were predicted in
that speciﬁc area of the FUT1 promoter gene [31]. Since the human
FUT1 and FUT2 contain multiple HIF transcription factor consensus
sequences (data not shown) it is possible that HIF-1a binds directly
to regulatory repressor regions in the promoter of these genes,
thereby preventing their transcription. We showed nuclear expres-
sion of HIF-1a in PaTu-T cells, which indeed suggests a role of
HIF-1a in gene transcription. However, alternative mechanisms
of FUT1/2 modulation by HIF-1 cannot be excluded. Both FUT1
and FUT2 expression could be negatively regulated by one of the
abundant micro-RNAs induced by HIF-1 [32], or via dislocation
by HIF-1 of other transcription factors from FUT gene promoters,
in a similar fashion as observed for c-Myc [33] or due to down reg-
ulation via alternative splicing of the FUT1/2mRNA by HIF-1a [34–
36]. Furthermore, although improbable, we cannot dismiss the
possibility that HIF-1a suppression could be an indirect effect of
pure competition for ARNT1 (HIF-1b) availability in these cells,
since the latter factor can participate in transcriptional regulation
independent of HIF-1a. By decreasing HIF-1a protein, ARNT is
available to bind other transcription factors such as was shown
for SP1 [37] and consequently induce FUT1/2 transcription.
In conclusion, our data demonstrate that HIF-1a can negatively
regulate FUT1 and FUT2 expression in PDAC cells, resulting in low-
ered expression of a1,2-fucosylated glycans on the cell surface.
Together, these data increase our understanding in the factors that
contribute to the complex regulation of glycosylation in cancer.
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